Guideline: LNDTA Guidelines (Lithuania): Difference between revisions
From Beacon
m (Victor moved page LNDTA Guidelines (Lithuania) to Guideline: LNDTA Guidelines (Lithuania)) |
m (Update categories.) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
<span style="display:none">forproviders</span> <span style="display:none">forpolicymakers</span> | <span style="display:none">forproviders</span> <span style="display:none">forpolicymakers</span> | ||
<span style="display:none">lithuaniacountry</span> | |||
Go back to [[Lithuania]] page | Go back to [[Lithuania]] page | ||
| Line 19: | Line 20: | ||
<span style="display:none">availableVariable::diagnosis</span> | <span style="display:none">availableVariable::diagnosis</span> | ||
<span style="display:none">availableVariable::medical procedures|treatments</span> | <span style="display:none">availableVariable::medical procedures|treatments</span> | ||
<span style="display:none">isPracticeGuideline</span> | |||
<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> | <span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | |||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | |||
<span style="display:none">Renal</span> | |||
<span style="display:none">Urothelial</span> | |||
<span style="display:none">Ureteral</span> | |||
<span style="display:none">Urethral</span> | |||
Latest revision as of 12:03, 14 December 2025
Go back to Lithuania page
Sponsor, manager or home institution: Lietuvos nefrologijos, dializės ir transplantacijos asociacijos.
Primary purpose: To prepare recommendations on how to optimize the diagnosis and treatment of kidney diseases.
Type of information: Recommendations, diagnosis, monitoring, evaluation and treatments of kidney diseases. Click here to learn more.
Cancer areas of interest: C64-C68: Urinary system cancers. Click here to learn more.
Access to information: Click here to access.
